Abdulraheem Yacoub, MD

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

The panel explains the standards for symptom assessment in patients with myelofibrosis and how often patients are monitored.

Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.

Dr Jamile Shammo discusses how to approach sequencing therapies in patients with myelofibrosis and Dr Raajit Rampal explains the potential of the JAK inhibitor momelotinib in the treatment of myelofibrosis.

Raajit Rampal, MD, and Abdulraheem Yacoub, MD, review data on the use of pacritinib and fedratinib in patients with myelofibrosis.

Jamile Shammo, MD, comments the currently approved treatment options for patients with myelofibrosis and review data from the COMFORT-I and COMFORT-II trials, which evaluates the use of ruxolitinib in MF.

Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.

The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.

Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Abdulraheem Yacoub, MD, discusses the rationale behind examining parsaclisib following suboptimal response to ruxolitinib in patients with myelofibrosis.

Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.